Graduate School of
Christopher J. Molloy, Ph.D., RPh
BS, (Pharmacy), Rutgers University
PhD, Rutgers University and UMDNJ
Post-Doc, National Cancer Institute, NIH
Dr. Molloy is a molecular and cellular pharmacologist with extensive drug discovery research and management experience in the biopharmaceutical industry. His specific research interests include the molecular mechanisms involved in inflammation and carcinogenesis, with an emphasis on the role of growth factors/cytokines and their intracellular signaling pathways in the control of tissue remodeling. Dr. Molloy has led multiple multidisciplinary drug discovery teams that have advanced new chemical entities from conception into human clinical trials in therapeutic areas such as inflammation, oncology, and cardiovascular disease. He joins Rutgers from Johnson & Johnson Pharmaceutical Research and Development, LLC. He also held senior research positions at 3-Dimensional Pharmaceuticals, Inc. and Bristol-Myers Squibb Pharmaceutical Research Institute.
Taylor, D.S., Cheng, X., Pawlowski, J.E., Wallace, A.R., Ferrer, P. and Molloy, C.J.: Epiregulin is a potent vascular smooth muscle cell-derived autocrine mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc. Natl. Acad. Sci. USA 96:1633-1633-1638, 1999.
Grasberger, B.L., Schubert, C., Koblish, H.K., Carver, T.E., Franks, C.F., Zhao, S., Lu, T., LaFrance, L.V., Parks, D.J., Milkiewicz, K.L., Calvo, R.R., Lattanze, J., Ramachandren, K., Petrella, E.C., Cummings, M.D., Manthey, C.L., Deckman, I.C., Maguire, D., Spurlino, J.S., Tomczuk, B.E., Bone, R.F., Salemme, F.R., Maroney, A.C., Pantoliano, M., Bylebyl, G., Zhang, M., Yurkow, E.J., Molloy, C.J. and Bone, R.: Discovery and co-crystal structures of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J.Med. Chem. 48:909-912, 2005.
Koblish, H.K., Zhao, S., Franks, C.F., Donatelli, R.R., Tominovish, R.M., LaFrance, L.V., Leonard, K.A., Gushue, J.M., Parks, D.J., Calvo, R.R., Milkiewicz, K.L., Marugan, J.J., Raboisson, P., Cummings, M.D., Grasberger, B.L., Johnson, D.L., Lu, T., Molloy, C.J., and Maroney, A.C.: Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Therap. 5:160-169, 2006.
Liem-Moolenaar, M., Cerneus, D., Molloy, C.J., End, D., Brown, K.H., de Kam, M., Cohen, A.F., van Hensbergen, Y., Burggraaf, J.: Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in man. Clin. Pharmacol. Ther. 84:481-487, 2008.
Meegalla SK, Wall MJ, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Illig CR. Structure-based optimization of a potent class of arylamide FMS inhibitors. Bioorg Med Chem Lett. 18:3632-3637, 2008
|1986||Biotechnology Fellowship Award, National Cancer Institute|
|1987||"Hot Paper" Award in The Scientist (Vol. 5) for the Nature publication entitled: "PDGF Induction of Tyrosine Phosphorylation of GTPase Activating Protein"|
|1988||Standards of Leadership Award, Johnson & Johnson|